In this edition:
Cabozantinib + nivolumab-ipilimumab in intermediate/poor-risk untreated advanced RCC
Adjuvant nivolumab + ipilimumab for localised RCC at risk of postnephrectomy relapse
Adjuvant atezolizumab in RCC at risk of postresection recurrence
Perioperative nivolumab for RCC undergoing nephrectomy
Bempegaldesleukin + nivolumab in previously untreated advanced RCC
First-line pembrolizumab + lenvatinib for non-clear-cell RCC
Belzutifan + cabozantinib in advanced RCC
Survivorship for first-line intermediate/poor-risk advanced RCC responders to nivolumab-ipilimumab
Long-term efficacy of nivolumab vs. everolimus in pretreated advanced RCC
In situ immune markers predict nivolumab ±ipilimumab efficacy in metastatic clear-cell RCC
Tailored approach with nivolumab and nivolumab-ipilimumab boost in metastatic RCC
Gut microbiota shift during ICI/TKI therapy in metastatic RCC
Please login below to download this issue (PDF)